These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 33090124)

  • 1. Correction to: Severe hypoglycemia caused by a small dose of repaglinide and concurrent use of nilotinib and febuxostat in a patient with type 2 diabetes.
    Komatsu H; Enomoto M; Shiraishi H; Morita Y; Hashimoto D; Nakayama S; Funakoshi S; Hirano S; Terada Y; Miyamura M; Fujimoto S
    Diabetol Int; 2020 Oct; 11(4):393. PubMed ID: 33090124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe hypoglycemia caused by a small dose of repaglinide and concurrent use of nilotinib and febuxostat in a patient with type 2 diabetes.
    Komatsu H; Enomoto M; Shiraishi H; Morita Y; Hashimoto D; Nakayama S; Funakoshi S; Hirano S; Terada Y; Miyamura M; Fujimoto S
    Diabetol Int; 2020 Oct; 11(4):388-392. PubMed ID: 33088647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe hypoglycemia from clarithromycin-repaglinide drug interaction.
    Khamaisi M; Leitersdorf E
    Pharmacotherapy; 2008 May; 28(5):682-4. PubMed ID: 18447665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoglycemia during the Concomitant Use of Repaglinide and Clopidogrel in an Elderly Patient with Type 2 Diabetes and Severe Renal Insufficiency.
    Takayama K; Fujii K; Yamaguchi H; Miyoshi Y; Uehara Y; Nagata S; Obata Y; Kosugi M; Hazama Y; Yasuda T
    Intern Med; 2021; 60(6):905-910. PubMed ID: 33716254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction to: IAPP/amylin and β‑cell failure: implication of the risk factors of type 2 diabetes.
    Kanatsuka A; Kou S; Makino H
    Diabetol Int; 2018 Oct; 9(4):266. PubMed ID: 30605171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient.
    Roustit M; Blondel E; Villier C; Fonrose X; Mallaret MP
    Ann Pharmacother; 2010 Apr; 44(4):764-7. PubMed ID: 20197475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serious hypoglycemia associated with misuse of repaglinide.
    Flood TM
    Endocr Pract; 1999; 5(3):137-8. PubMed ID: 15251685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction to: Japanese Clinical Practice Guideline for Diabetes 2016.
    Haneda M; Noda M; Origasa H; Noto H; Yabe D; Fujita Y; Goto A; Kondo T; Araki E
    Diabetol Int; 2019 Jan; 10(1):83. PubMed ID: 30800567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction to: Japanese Clinical Practice Guideline for Diabetes 2016.
    Haneda M; Noda M; Origasa H; Noto H; Yabe D; Fujita Y; Goto A; Kondo T; Araki E
    Diabetol Int; 2020 Apr; 11(2):163. PubMed ID: 32206488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction to: Non-autoimmune acute-onset type 1 diabetes mellitus newly developed in an elderly patient presenting elevation of serum pancreatic exocrine enzymes.
    Kanzaki A; Matsuda M; Yokota S; Takai K; Murai J; Otsuka A; Koyama H; Nakamura T
    Diabetol Int; 2022 Jan; 13(1):314. PubMed ID: 35073563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction: Patients with gestational diabetes mellitus may be treated in both early and late pregnancy, especially in patients with pre-pregnancy overweight: A cross-sectional study in Japan.
    Takemoto A; Nagai Y; Kawanabe S; Nakagawa T; Matsumoto K; Hasegawa J; Suzuki N; Tanaka Y; Sone M
    Diabetol Int; 2024 Apr; 15(2):313. PubMed ID: 38524934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction: New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): Report from Committee on Type 1 Diabetes in Japan Diabetes Society (English version).
    Shimada A; Kawasaki E; Abiru N; Awata T; Oikawa Y; Osawa H; Kajio H; Kozawa J; Takahashi K; Chujo D; Noso S; Fukui T; Miura J; Yasuda K; Yasuda H; Imagawa A; Ikegami H
    Diabetol Int; 2024 Jul; 15(3):638-639. PubMed ID: 39101174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction: A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes.
    Bouchi R; Kondo T; Ohta Y; Goto A; Tanaka D; Satoh H; Yabe D; Nishimura R; Harada N; Kamiya H; Suzuki R; Yamauchi T
    Diabetol Int; 2023 Oct; 14(4):446. PubMed ID: 37781468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repaglinide and diabetes: new preparation. No better than glucose-lowering sulphonamides.
    Prescrire Int; 2001 Feb; 10(51):9-11. PubMed ID: 11503861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2].
    Rutten GE
    Ned Tijdschr Geneeskd; 2001 Aug; 145(32):1547-50. PubMed ID: 11525087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction to: Glycemic control of people with diabetes over months after the 2018 North Osaka Earthquake.
    Watanabe H; Takahara M; Katakami N; Matsuoka TA; Shimomura I
    Diabetol Int; 2022 Jan; 13(1):336. PubMed ID: 35059273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Hypoglycemia and Concomitant Use of Repaglinide and Clopidogrel: A Population-Based Nested Case-Control Study.
    Wei Y; Lin FJ; Lin SY; Wang CC
    Clin Pharmacol Ther; 2019 Dec; 106(6):1346-1352. PubMed ID: 31216051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study.
    Jovanovic L; Dailey G; Huang WC; Strange P; Goldstein BJ
    J Clin Pharmacol; 2000 Jan; 40(1):49-57. PubMed ID: 10631622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction: Trends in clinical characteristics and factors associated with initial prescription of SGLT2 inhibitors in Japanese patients with type 2 diabetes mellitus.
    Takahashi H; Suganuma Y; Ohno T; Nishimura R
    Diabetol Int; 2024 Jan; 15(1):141. PubMed ID: 38264230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction to: Impact of actual waiting time and perceived waiting time on treatment satisfaction in patients receiving outpatient diabetes care.
    Toga-Sato S; Tosaki T; Kondo M; Tsunekawa S; Kato Y; Nakamura J; Kamiya H
    Diabetol Int; 2021 Jul; 12(3):301-302. PubMed ID: 34157059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.